SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (9)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Lloyd, A. J.
Right arrow Articles by Young, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lloyd, A. J.
Right arrow Articles by Young, A. H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The Pharmacological Treatment of Bipolar Affective Disorder: Practice Is Improving but Could Still be Better

Adrian J. Lloyd

C. Louise Harrison

I. Nicol Ferrier

Allan H. Young

School of Neurology Neurobiology and Psychiatry, University of Newcastle, Newcastle upon Tyne and Psychiatry, Leazes Wing, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

Pharmacological treatment of bipolar affective disorder was examined by case note review of 120 subjects under the care of four hospitals in the North-East of England and compared with that recommended in published consensus opinions and also with the findings of previous surveys. Although the only comparison available is with other geographical regions, it appears that lithium use has remained relatively constant in recent years (53% in this sample). The use of anticonvulsants (62%) was greater than in previous studies, as was use of mood stabilizers in combination (37% overall, 53% in rapid cycling subjects). Antidepressant use was found in 23% of subjects. Eleven percent of subjects taking antidepressants were not prescribed a mood stabilizer and 43% of antidepressants prescribed were tricyclics, possibly increasing the risk of switching to mania. Fifteen percent had no mood stabilizer and antipsychotic use was almost equally split between typical and atypical drugs. Practice in the population studied is nearer than treatment described in previous work to that suggested in the literature. This may result from either, or most probably a combination of, the local availability of a specialist mood disorder service and evolution of overall prescribing practice. However, it still falls short in a number of respects of such recommendations as exist and this requires further examination and monitoring.

Key Words: anticonvulsants • antidepressants • antipsychotics • bipolar disorder • lithium • mood stabilizers • treatment

Journal of Psychopharmacology, Vol. 17, No. 2, 230-233 (2003)
DOI: 10.1177/0269881103017002013


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
A. Streeruwitz, T. R. E. Barnes, J. Fehler, R. Ohlsen, and V. A. Curtis
Pharmacological management of acute mania - does current prescribing practice reflect treatment guidelines?
J Psychopharmacol, March 1, 2007; 21(2): 206 - 209.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
N. Farrelly, C. Dibben, and N. Hunt
Current management of bipolar affective disorder: Is it reflective of the BAP guidelines?
J Psychopharmacol, January 1, 2006; 20(1): 128 - 131.
[Abstract] [PDF]


Home page
Psychiatr. Serv.Home page
J. F. Goldberg, M. H. Allen, D. A. Miklowitz, C. L. Bowden, C. J. Endick, C. A. Chessick, S. R. Wisniewski, S. Miyahara, K. Sagduyu, M. E. Thase, et al.
Suicidal Ideation and Pharmacotherapy Among STEP-BD Patients
Psychiatr Serv, December 1, 2005; 56(12): 1534 - 1540.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
C. H. Ashton, P. B. Moore, P. Gallagher, and A. H. Young
Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential
J Psychopharmacol, May 1, 2005; 19(3): 293 - 300.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
I. M. Anderson, P. M. Haddad, and I. Chaudhry
Changes in Pharmacological treatment for Bipolar Disorder Over Time in Manchester: A Comparison with Lloyd et al. (2003)
J Psychopharmacol, September 1, 2004; 18(3): 441 - 444.
[PDF]



Advertisement